{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:07:55Z","timestamp":1774415275476,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"German Federal Ministry of Education and Research","doi-asserted-by":"publisher","award":["03VP03980"],"award-info":[{"award-number":["03VP03980"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.xphs.2020.03.012","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T21:01:00Z","timestamp":1584651660000},"page":"2090-2094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs"],"prefix":"10.1016","volume":"109","author":[{"given":"Max","family":"Sauter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas D.","family":"Meid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2020.03.012_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jpba.2019.06.015","article-title":"An ultra-sensitive UHPLC-MS\/MS assay for the quantification of orally administered vancomycin in plasma","volume":"174","author":"Sauter","year":"2019","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2020.03.012_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/j.1552-4604.1980.tb01696.x","article-title":"Single-dose kinetics of intravenous vancomycin","volume":"20","author":"Krogstad","year":"1980","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2020.03.012_bib4","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/AAC.22.3.391","article-title":"Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations","volume":"22","author":"Rotschafer","year":"1982","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.xphs.2020.03.012_bib6","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1093\/clinids\/3.Supplement_2.S230","article-title":"Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function","volume":"3","author":"Moellering","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40262-018-0727-5","article-title":"Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations","volume":"58","author":"Colin","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2020.03.012_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Michael Rybak","year":"2009","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.xphs.2020.03.012_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00605631","article-title":"Multicompartment pharmacokinetics of netilmicin","volume":"16","author":"Wenk","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2020.03.012_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.1977.03280040047019","article-title":"Tissue persistence of gentamicin in man","volume":"238","author":"Schentag","year":"1977","journal-title":"JAMA"},{"key":"10.1016\/j.xphs.2020.03.012_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.19.5.859","article-title":"Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients","volume":"19","author":"Schentag","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2020.03.012_bib12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.14.4.634","article-title":"Safety of oral vancomycin in functionally anephric patients","volume":"14","author":"Bryan","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2020.03.012_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.25.4.433","article-title":"Pharmacokinetics of vancomycin in patients with various degrees of renal function","volume":"25","author":"Matzke","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2020.03.012_bib14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jcp.48.7.689-b","article-title":"Systemic absorption of vancomycin","volume":"48","author":"Armstrong","year":"1995","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.xphs.2020.03.012_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/phar.1538","article-title":"Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection","volume":"35","author":"Pettit","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.xphs.2020.03.012_bib16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/00365548.2010.544671","article-title":"Systemic absorption of oral vancomycin in patients with Clostridium difficile infection","volume":"43","author":"Rao","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib17","first-page":"426","article-title":"A\u00a0prospective pilot study on the systemic absorption of oral vancomycin in children with colitis","volume":"21","author":"Antoon","year":"2016","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"key":"10.1016\/j.xphs.2020.03.012_bib18","series-title":"Plasma Vancomycin Concentrations in Patients with Clostridium difficile Infection Taking Oral Vancomycin. Poster P1623, 22nd ECCMID","author":"Donskey","year":"2012"},{"key":"10.1016\/j.xphs.2020.03.012_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0272-6386(87)80146-4","article-title":"Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis","volume":"5","author":"Matzke","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fmed.2017.00070","article-title":"The effects of fasting and massive diarrhea on absorption of enteral vancomycin in critically ill patients: a retrospective observational study","volume":"4","author":"Oami","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.xphs.2020.03.012_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.7326\/0003-4819-101-1-144_1","article-title":"Absorption of vancomycin","volume":"101","author":"Dudley","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xphs.2020.03.012_bib22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jiac.2017.08.004","article-title":"An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency","volume":"23","author":"Yamazaki","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.xphs.2020.03.012_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/00365548.2010.513066","article-title":"Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis","volume":"43","author":"Chihara","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-100-4-533","article-title":"Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis","volume":"100","author":"Spitzer","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xphs.2020.03.012_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.smj.0000216477.06918.a3","article-title":"Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function","volume":"99","author":"Aradhyula","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.xphs.2020.03.012_bib26","first-page":"315","article-title":"Oral absorption of enteral vancomycin in a child with Clostridium difficile colitis and renal impairment","volume":"18","author":"Wood","year":"2013","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"key":"10.1016\/j.xphs.2020.03.012_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/j.2055-2335.2011.tb00867.x","article-title":"Systemic absorption from oral vancomycin: check the dose!","volume":"41","author":"Coutsouvelis","year":"2011","journal-title":"J\u00a0Pharm Pract Res"},{"key":"10.1016\/j.xphs.2020.03.012_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/j.2055-2335.2005.tb00346.x","article-title":"Systemic absorption of low-dose oral vancomycin","volume":"35","author":"Brouwer","year":"2005","journal-title":"J\u00a0Pharm Pract Res"},{"key":"10.1016\/j.xphs.2020.03.012_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0140-6736(93)92861-M","article-title":"Systemic absorption after local intracolonic vancomycin in pseudomembranous colitis","volume":"342","author":"Pasic","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2020.03.012_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1399-3062.2009.00426.x","article-title":"Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract","volume":"11","author":"Pogue","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.xphs.2020.03.012_bib31","first-page":"1","article-title":"Absorption of oral vancomycin - possible associated toxicity","volume":"4","author":"Thompson","year":"1983","journal-title":"Int J Pediatr Nephrol"},{"key":"10.1016\/j.xphs.2020.03.012_bib32","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.xphs.2020.03.012_bib33","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.xphs.2020.03.012_bib34","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1208\/s12248-015-9743-7","article-title":"Applying biopharmaceutical classification system (BCS) criteria to predict oral absorption of drugs in dogs: challenges and pitfalls","volume":"17","author":"Papich","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2020.03.012_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejps.2013.08.018","article-title":"Animal versus human oral drug bioavailability: do they correlate?","volume":"57","author":"Musther","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2020.03.012_bib36","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.2146\/ajhp170200","article-title":"Serum vancomycin concentrations after oral and intracolonic vancomycin administration in a patient with colonic discontinuity and severe Clostridium difficile infection","volume":"75","author":"Wilke","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.xphs.2020.03.012_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF01059684","article-title":"Gentamicin disposition and tissue accumulation on multiple dosing","volume":"5","author":"Schentag","year":"1977","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.xphs.2020.03.012_bib38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.13.4.649","article-title":"Accumulation pharmacokinetics of tobramycin","volume":"13","author":"Schentag","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl C","key":"10.1016\/j.xphs.2020.03.012_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/27.suppl_C.41","article-title":"Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man","volume":"27","author":"De Broe","year":"1991","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920301386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920301386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:28:51Z","timestamp":1758360531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920301386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0022354920301386"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.03.012","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}